CD4+ Th1 to the rescue in HER-2+ breast cancer.
HER2 overexpression leads to downregulation of MHC class-I. CD4+ Th1 cytokines, IFNγ and TNFα, and monoclonal antibodies, trastuzumab and pertuzumab, restore MHC class-I expression, and enable CD8+ recognition and cytolysis. Restoration of the anti-HER2 CD4+ Th1 immune response in combination with HER2 targeted therapy appear to be critical to successful anti-HER2 CD8+ immunotherapy.
['Lowenfeld|Lea|L|', 'Xu|Shuwen|S|', 'Czerniecki|Brian J|BJ|']
HER2 IFNγ TNFα monoclonal antibodies trastuzumab pertuzumab MHC class-I CD4+ T-cells CD8+ T-cells